Bridging the Gap After a Suicidal Crisis: A New Idea Under Study

[Chip (OP)]

📎 Click on me to view all my attachmentsTheme: Deep IndigoMidnight DarkPink & PurpleSlate GraySolarized LightEmerald GreenCyberpunk NeonNordDraculaSunset OrangeWarm AmberOcean BreezeClassic LightCrimson DuskMatrix TerminalCoffee & CreamAutumn FrostRetro TerminalLavender MistNordic FrostMonochrome SlateTeal BreezeNo theme (plain)

ListAttBBC  |  v7.3.0  |  2026-10-26  |  Andrew.human & Claude.ai  |  live 18:23:47

#	File	Size	Downloads	Info	DL
00	bridging_the_gap_after_a_suicidal_crisis.md	7.1 KB	0	ℹ️	⬇️
Attachment ID 8746 Filename (display) bridging_the_gap_after_a_suicidal_crisis.md File extension md MIME type Size 7.1 KB (7282 bytes) Downloads 0 Dimensions n/a Uploaded by Guest Message ID 49969 Attachment type Normal attachment (0) Storage folder ID 2 Thumbnail attach ID none File hash ab4bb497eac4686852982d7a0bb7ddb996e24d07 Approved Yes Filename (on disk) 8746_ab4bb497eac4686852982d7a0bb7ddb996e24d07 Storage directory 2 (/var/www/html/attachments2) File exists on disk? Yes (core)
No recorded downloads yet.

https://www.psychiatrist.com/jcp/bridging-suicidal-crisis-outpatient-care-ketamine-plus-buprenorphine

Bridging Suicidal Crisis to Outpatient Care: Could Ketamine Plus Buprenorphine Shift the Paradigm ?

Oct 19, 2026

Introduction (see the entire article at the source link above):

Acute suicidal crisis is a common, high-stakes presentation in emergency departments (EDs) across the US, with few treatment options for rapid and durable relief of symptoms. Due to the inconsistent availability of mental health care across the country, EDs represent a common first touchpoint for patients in suicidal crisis.

Current standard of care for patients in suicidal crisis is limited to determining the need for inpatient versus outpatient care, with few therapeutic interventions initiated in the ED. Patients requiring psychiatric hospitalization often remain in the ED for prolonged boarding while awaiting placement. While ketamine is well established to reduce suicidal ideation in outpatients with major depression and suicidal ideation within hours, there remain significant questions to be answered before its use can be adopted in ED patients.

In a recent randomized controlled trial, adjunctive low-dose buprenorphine following a single ketamine infusion may prolong reductions in suicidal ideation for up to 1 month (Tucciarone et al, 2026).1 However, these findings remain preliminary and require replication before clinical implementation. Here, we review the emerging evidence on therapeutic strategies that may help bridge patients presenting to the ED in suicidal crisis to outpatient care, consider the potential implications for emergency medicine clinicians, and highlight key priorities for future clinical trials.

Burden of Acute Suicidal Crises in EDs

Suicidal ideation and acute suicidal crisis are increasingly common reasons for ED visits.2 Nearly 1.4 million ED visits each year involve suicidal ideation or attempt, and that number continues to rise. For many patients, the ED is the first point of contact with the mental health system, yet treatment options in the acute setting remain limited.

Patients deemed to be at high risk for suicide are often held in the ED until an inpatient psychiatric bed becomes available. ED boarding, defined as the time between the decision to admit and transfer from the ED because no inpatient bed is available, has become increasingly common, increases emotional distress, delays definitive psychiatric care, contributes to ED crowding, and is associated with longer hospital stays and medication errors.3–5

Importantly, not every patient presenting to the ED with suicidal ideation benefits from inpatient psychiatric hospitalization.4  Treatments for suicidal crisis in the ED, whether pharmacologic or behavioral, are not widely available. Many patients leave the ED with limited access to outpatient psychiatric care, particularly in rural and underserved communities.6 Without timely follow-up, patients remain vulnerable to recurrent suicidal crises and repeat ED visits.7 Improving continuity of care after suicidal crisis remains a national priority.8

Ketamine: A Familiar Drug That Could Provide Rapid but Transient Relief

Current evidence suggests that for patients with treatment resistant depression with or without suicidal crisis, ketamine infusion can produce a rapid, yet transient antisuicidal effect in the outpatient setting.9–11 Unlike conventional antidepressants, a single dose of IV ketamine can reduce suicidal ideation within hours, and its effects may persist for 1 to 4 weeks.

Several factors make ketamine a potential choice for management of suicidal crisis in patients, particularly within EDs.

First, ketamine has a rapid onset, and whether or not a patient will respond to treatment could be determined within the first hours of an ED encounter.

Second, ketamine is already widely available for procedural sedation, analgesia, and management of severe agitation in nearly every ED across the US and is a drug with which ED physicians are already comfortable.

Third, small clinical trials suggest ketamine can be administered safely to patients with suicidal ideation in the ED.9,12,13 Finally, beyond reducing suicidal ideation, ketamine rapidly improves several symptoms such as depression, hopelessness, pessimism, and irritability, which suggests that its clinical benefit may extend beyond a single symptom domain.14,15

There remain significant unanswered questions before ketamine use for this indication can be widely adopted by ED clinicians. While ketamine is a promising candidate for investigation in ED patients, further trials, including that by Maguire (NCT06085937), remain ongoing to determine whether its benefits in outpatients will translate to an ED population of suicidal adults. While pilot studies show evidence of feasibility, robust evidence of feasibility and efficacy in an ED population remains needed.12,13 In addition, these studies commonly exclude patients who are intoxicated, have a history of psychosis, or have experienced recent manic episodes, limiting generalizability of findings to these populations. Should ongoing trials support the use of ketamine for this indication, there remain questions to be addressed before widespread adoption of its use could be expected. Identifying which ED patients may or may not benefit from a trial of ketamine remains a challenge. In addition, while a single dose of ketamine can reduce suicidal ideation for up to several weeks, the range of efficacy is days to weeks, and ongoing care would need to be reliably and rapidly initiated.9 Like many ED-based therapies, a single dose of ketamine in the ED could not be considered definitive care, though it could start a bridge to outpatient rather than pursuing inpatient treatment for selected patients. Developing a robust outpatient pathway for continued care in those who respond to an initial dose of ketamine remains necessary.